Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail

Molecular Endocrinology

Volumn 10, Issue 10, 1996, Pages 1206-1213

  Allan, George F ^a   Lombardi, Elizabeth ^a   Haynes Johnson, Donna ^a   Palmer, Stephen ^a   Kiddoe, Margaret ^a   Kraft, Patricia ^a   Campen, Carolyn ^a   Rybczynski, Philip ^a   Combs, Donald W ^a   Phillips, Audrey ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROMEGESTONE; RWJ 26819; RWJ 47626; UNCLASSIFIED DRUG; ZK 299; ZM 574;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; BINDING SITES; GONANES; HORMONE ANTAGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; PROMEGESTONE; PROTEIN CONFORMATION; RECEPTORS, PROGESTERONE; SEQUENCE ANALYSIS;

EID: 10144242689     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.10.10.1206     Document Type: Article

References (43)

1. Yen SSC 1993 Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ (eds) Clinical Applications of Mifepristone (RU-486) and Other Antiprogestins. National Academy Press, Washington, DC, pp 189-209
2. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS 1993 Regression of uterine leiomyomata in response to the antiprogesterone RU-486. J Clin Endocrinol Metab 76:513-517
3. Grunberg SM 1994 Role of antiprogestational therapy for meningiomas. Hum Reprod 91:202-207
4. Bakker GH, Setyono-Han B, Portengen H, de Jong FH, Foekens JA, Klijn JGM 1990 Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789-794
5. Glasier A, Thong KJ, Dewar M, Mackie M, Baird 1992 Mifepristone (RU486) compared with high dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 327:1041-1044
6. Stiemer B, Elger W 1990 Cervical ripening of the rat in dependence on endocrine milieu; effects of antigestagens. J Perinatal Med (Berl) 18:419-429
7. Klein-Hitpass L, Cato ACB, Henderson D, Ryffel GU 1991 Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19:1227-1234
8. Allan, G 1994 Mechanism of ligand activation. In: Tsai, M-J, O'Malley, BW (eds) Mechanism of Steroid Hormone Regulation of Gene Transcription. RG Landes, Austin, TX, pp 71-92
9. Meyer M-E, Pornon A, Ji J, Bocquel M-T, Chambon P, Gronemeyer H 1990 Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9:3923-3932
10. Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD 1989 Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen- stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 52:1055-1060
11. Chwalisz K, Hegele-Hartung C, Fritzemeier K-H, Beier HM, Elger W 1991 Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors. Endocrinology 129:312-322
12. Takimoto GS, Tasset DM, Eppert AC, Horwitz KB 1992 Hormone-induced progesterone receptor phosphorylation consists of sequential DMA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89:3050-3054
13. Delabre K, Guiochon-Mantel A, Milgrom E 1993 In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421-4425
14. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520
15. Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP 1992 Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol 6:1585-1597
16. Beekman JM, Allan GF, Tsai SY, Tsai M-J, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266-1274
17. Leng X, Tsai SY, O'Malley BW, Tsai M-J 1993 Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoid X receptor. J Steroid Biochem Mol Biol 46:643-661
18. Zeng Z, Allan GF, Thaller C, Cooney AJ, Tsai SY, O'Malley BW, Tsai M-J 1994 Detection of potential ligands for nuclear receptors in cellular extracts. Endocrinology 135:248-252
19. Bhat MK, Parkison C, McPhie P, Liang C-M, Cheng S 1993 Conformational changes of human ß1 thyroid hormone receptor induced by binding of 3,3′,5-triiodo-L-thyronine. Biochem Biophys Res Commun 195:385-392
20. Keidel S, LeMotte P, Apfel C 1994 Different agonist-induced and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Cell Biol 14:287-298
21. Leid M 1994 Ligand-induced alteration of the protease sensitivity of retinoid X receptor a. J Biol Chem 269:14175-14181
22. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270:27569-27576
23. Trapp T, Holsboer F 1995 Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215:286-291
24. Clemm DL, Macy BL, Santiso-Mere D, McDonnell DP 1995 Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. J Steroid Biochem Mol Biol 53:487-495
25. Combs DW, Reese K, Phillips A 1995 Nonsteroidal progesterone receptor ligands. 1. 3-aryl-1-benzoyl-1,4,5,6-tetrahydropyridazines. J Med Chem 38:4878-4879
26. Palmer S, Allan G, Campen C, Combs DW, Forrester M, Lai MT, Kraft P, Haynes-Johnson D, Riesenberg M, Williams RF, Hodgen GD, Phillips A, RWJ 26819, a non-steroidal progestin receptor ligand with unprecedented receptor selectivity, in vivo agonist activity. Program of the 77th Annual Meeting of The Endocrine Society, Washington, DC, 1995, p 228 (Abstract)
27. Mitchell WM, Harrington WF 1970 Clostripain. In: Perlmann GE, Lorand L (eds) Methods in Enzymology. Proteolytic Enzymes. Academic Press, New York, vol 19:635-642
28. Blumberg B, Bolado Jr J, Derguini F, Craig AG, Moreno TA, Chakravarti D, Heyman RA, Buck J, Evans RM 1996 Novel retinoic acid receptor ligands in Xenopus embryos. Proc Natl Acad Sci USA 93:4873-4878
29. Wilcox PE 1970 Chymotrypsinogens-chymotrypsins. In: Perlmann GE, Lorand L (eds) Methods in Enzymology. Proteolytic Enzymes. Academic Press, New York, vol 19:64-108
30. Fawell SE, Lees JA, White R, Parker MG 1990 Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60:953-962
31. Beck CA, Zhang Y, Weigel NL, Edwards DP 1996 Two types of anti- progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271:1209-1217
32. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP 1993 The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 90:4441-4445
33. Sartorius CA, Tung L, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 268:9262-9266
34. Nordeen SK, Bona BJ, Moyer ML 1993 Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 7:731-742
35. Danielian PS, White R, Lees JA, Parker MG 1992 Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033
36. Saatcioglu F, Bartunek P, Deng T, Zenke M, Karin M 1993 A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor). Mol Cell Biol 13:3675-3685
37. Lanz RB, Rusconi S 1994 A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinology 135:2183-2195
38. Nagpal S, Friant S, Nakshatri H, Chambon P 1993 RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 12:2349-2360
39. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 375:377-382
40. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-7 ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689
41. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713
42. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
43. El-Ashry D, Onate SA, Nordeen SK, Edwards DP 1989 Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558